GRAIL (NASDAQ:GRAL) CFO Sells 4,100 Shares of Stock

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 4,100 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $93.34, for a total value of $382,694.00. Following the sale, the chief financial officer directly owned 248,983 shares in the company, valued at $23,240,073.22. This trade represents a 1.62% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Freidin also recently made the following trade(s):

• On Thursday, August 27th, Aaron Freidin sold 7,900 shares of GRAIL stock. The shares were sold at an average price of $85.01, for a total value of $671,579.00.

GRAIL Trading Up 1.3%

Shares of GRAL stock traded up $1.39 during trading hours on Wednesday, reaching $109.91. The stock had a trading volume of 1,075 shares, compared to its average volume of 945,800. The stock’s fifty day simple moving average is $75.56 and its 200 day simple moving average is $64.31. GRAIL, Inc. has a 12 month low of $41.50 and a 12 month high of $118.84. The firm has a market capitalization of $4.91 billion, a PE ratio of -11.27 and a beta of 3.25.

GRAIL (NASDAQ:GRAL) last posted its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The business had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. As a group, equities research analysts anticipate that GRAIL, Inc. will post -10.41 EPS for the current fiscal year.

Institutional Trading of GRAIL

Large investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd purchased a new position in GRAIL during the fourth quarter valued at $28,000. Fifth Third Bancorp grew its position in shares of GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after buying an additional 472 shares during the period. Allworth Financial LP bought a new position in shares of GRAIL in the 2nd quarter worth about $35,000. Geneos Wealth Management Inc. increased its stake in shares of GRAIL by 160.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after acquiring an additional 360 shares in the last quarter. Finally, Osbon Capital Management LLC purchased a new position in GRAIL during the 4th quarter valued at about $51,000.

Analysts Set New Price Targets

Several research analysts have commented on GRAL shares. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a research note on Sunday, September 13th. Royal Bank Of Canada started coverage on shares of GRAIL in a research report on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of GRAIL in a research report on Friday, June 5th. They set a “neutral” rating and a $60.00 price target for the company. Wolfe Research started coverage on GRAIL in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Finally, Robert W. Baird boosted their target price on GRAIL from $96.00 to $118.00 and gave the company an “outperform” rating in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $75.10.

About GRAIL

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.